Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2015–2018

ClickGene · Click Chemistry for Future Gene Therapies to Benefit Citizens, Researchers and Industry

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-01-01 → 2018-12-31
Финансиране от ЕС
3 556 990 €
Участници
18
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Нови методи в химията и нанотехнологиите се използват за създаване на инструменти за генно заглушаване и сонди за откриване на епигенетични промени в ДНК. Те помагат за развитието на персонализираната медицина и подобряването на генната терапия при хора и растения.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Click Chemistry for Future Gene Therapies to Benefit Citizens, Researchers and Industry

Gene therapy is expected to play a key role in next-generation medicine by correcting the underlying genetic causes of disease, thereby facilitating a personalised approach to medicine. As this technology can address a wide range of medical conditions, along with finding substantive application within plant genetics, extensive growth in this sector of the biopharmaceutical and agricultural industry are widely predicted. Thus, to enhance the human understanding and application of gene therapy, highly qualified experts of this field are urgently required. ClickGene addressed this need by providing cross-disciplinary training to 14 early-stage researchers (ESRs) in an exciting academia-industry collaboration focused on the development of next-generation gene silencing therapeutics and epigenetic DNA probes. The main goal of the European Training Network (ETN) ClickGene was to develop new materials and methodologies for site-selective genetic engineering by training researchers within an innovative, multi-disciplinary and entrepreneurial environment so that they can meet the challenges facing future scientific leaders in Europe’s industry. Over the four project years, our multidisciplinary consortium provides world-class training to the ESRs in the areas of synthetic click chemistry, nanotechnology, liposomal drug delivery and nucleic acid (DNA and RNA) chemistry. We generated scientific excellence and technological innovation in the areas of gene silencing and epigenetic base detection by generating 1) unique gene silencing tools that interact with DNA in a fundamentally different way compared with current start-of-art-technology on the market, 2) new liposomal and nanoparticle drug delivery agents, and 3) novel fluorogenic probes for epigenetic base detection in high-throughput PCR assays. These objectives are important for society as this network has trained the next generation of leading scientists in critical research fields that are required to maintain and enhance EU competitiveness in the areas of gene editing technology, nanotechnology, and nucleic acid chemistry. As such, this network has enhanced biopharmaceutical, biodiagnostic, and agricultural EU societal sectors. Secondly, the scientific and technological advantages for developing new tools for gene editing, epigenetic base detection, and nanoparticle drug delivery are all important for mankind and strive toward improving healthcare and the availability of cutting-edge biomedical diagnostics for European citizens and beyond.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Gene therapy is expected to play a key role in next-generation medicine by correcting the underlying genetic causes of disease, thereby facilitating personalised medicine. Current gene therapy methods possess undesirable side effects, including insertional mutagenesis, toxicity, low efficiency and off-target cutting. Questions also remain regarding the optimal methods for delivering nucleases into cells and tissues. These limitations will be addressed through the original and innovative approach of the ClickGene network. ClickGene’s research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, i.) site-selective genetic engineering, ii.) liposomal nanoparticle drug delivery, and iii.) optogenetic diagnostic probes for epigenetic base detection. Most of our academic partners are key members of COST Action CM1201: Biomimetic Radical Chemistry and all have outstanding international reputations as scientific leaders in their field. This COST Action will play a vital role in both networking and training elements of ClickGene, and in combination with transferable skills training, intersectorial and cross-disciplinary secondment, and industry targeted workshops, the education of biomaterials chemists with expertise in click-chemistry and cutting edge application areas of gene therapy, nanotechnology and biological diagnostics will be achieved. The training provided will match the skills required by next-generation research leaders in biopharmaceutical, nanotechnology, biodiagnostic and other industries. Allied to academic strength in this network, ClickGene features highlycompetitive industry partners with expertise in commercialisation of nucleic acid click-chemistry (baseclick, ATDBio) and liposomal and lipidome technology (LipiNutraGen). Thus, synergy between both commercial and academic partners will enable ESRs to develop gene-targeted technology within a highly productive, engaging, and exciting training network.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз